Ellington Management Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ellington Management Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,900	Closed	-$250K	–	484
2020 Q1	$250K	Buy	+4,900	New	+$328K	0.06%	375
2019 Q4	–	Sell	-17,900	Closed	-$869K	–	802
2019 Q3	$869K	Buy	+17,900	New	+$933K	0.16%	126
2018 Q2	–	Sell	-27,900	Closed	-$1.35M	–	944
2018 Q1	$1.35M	Buy	+27,900	New	+$1.56M	0.1%	126

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ellington Management Group's GBT Position: Q2 2020 in Review

Ellington Management Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 4,900 shares — an estimated $250K sold.

Ellington Management Group first reported a position in GBT in Q1 2018 and held it in 3 quarters. The position peaked at $1.35M in Q1 2018. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

Ellington Management Group reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 4,900 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $250K.
Ellington Management Group first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
Ellington Management Group's Global Blood Therapeutics, Inc. position peaked at $1.35M in Q1 2018.
253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.